












## Supplementary Material

**Table S1.** In vitro drug sensitivity testing results


Case no.	Dose-response curve	Selected drugs	Case no.	Dose-response curve	Selected drugs
1		Toceranib	6		Toceranib
2		Toceranib	7		Toceranib
3		Toceranib	8		Toceranib
4		Toceranib	9		Toceranib
5		Toceranib	10		Doxorubicin
Case no.	Dose-response curve	Selected drugs	Case no.	Dose-response curve	Selected drugs

11




Toceranib

14




Imatinib

12




Doxorubicin

15




Toceranib

13



Toceranib

16



Toceranib

**Table S2.** Adverse events observed in dogs treated with TKIs and conventional chemotherapy

Category	Targeted therapy (n=26)					Conventional chemotherapy (n=7)				
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Constitutional										
Lethargy	5					5				
Gastrointestinal										
Inappetence	5	2				3	1			
Anorexia							1	1		
Vomiting	1	1				1	1	1		
Diarrhea	2	3					3	1		
Hematologic										
Anemia						1				
Neutropenia	6	1				1		1		
Thrombocytopenia										
Biochemical										
Increased ALT	2					1				
Increased AST	4									
Increased ALP	1								1	
Renal										
Proteinuria			1							
Cardiovascular										
Hypertension	1									
Total	27	7	1	0	0	12	6	4	1	0

*Note:* Adverse events were evaluated according to the Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2.0).

Abbreviation: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase.